Physician profile
James Bernard
NPI 1477574044
$1,502.59
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.84 · 2020: $89.77 · 2021: $201 · 2022: $703 · 2023: $390 · 2024: $20.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $841.09 | 2019-2024 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $176.16 | 2021-2023 | Tremfya |
| Incyte Corporation | $116.72 | 2021-2023 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $56.63 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.21 | 2020-2023 | Duobrii, Arazlo, Jublia |
| Almirall LLC | $54.89 | 2021-2023 | Seysara |
| Sun Pharmaceutical Industries INC. | $41.76 | 2022 | |
| Lilly USA, LLC | $32.72 | 2020-2022 | |
| Journey Medical Corporation | $29.10 | 2022 | |
| Leo Pharma INC. | $19.62 | 2019 | |
| Galderma Laboratories, L.P. | $17.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.45 | 2022 | |
| Encore Dermatology INC. | $14.17 | 2020 | |
| Pfizer INC. | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.